Taysha Gene Therapies (TSHA) Equity Ratio (2019 - 2026)

Taysha Gene Therapies has disclosed Equity Ratio across 8 years of filings, most recently posting 0.71 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.71, up 77.33% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.71 (up 77.33% YoY), and the FY2025 annual result was 0.72, up 61.26% from the prior year.
• Equity Ratio came in at 0.71 for Q1 2026 at Taysha Gene Therapies, down from 0.72 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.75 in Q2 2025 to a low of 0.46 in Q2 2023.
• The 5-year median for Equity Ratio is 0.4 (2025), against an average of 0.31.
• Peak annual rise in Equity Ratio reached 5672.72% in 2023, while the deepest fall reached 361.28% in 2023.
• Taysha Gene Therapies' Equity Ratio stood at 0.01 in 2022, then jumped by 5672.72% to 0.43 in 2023, then climbed by 2.81% to 0.45 in 2024, then soared by 61.26% to 0.72 in 2025, then retreated by 1.89% to 0.71 in 2026.
• The last three Equity Ratio figures came in at 0.71 (Q1 2026), 0.72 (Q4 2025), and 0.69 (Q3 2025), per Business Quant data.